Women taking atypical antipsychotic medications have about a threefold higher prevalence of lower urinary tract symptoms (LUTS) compared to nonusers, a recent study has found.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.